Affiliation:
1. Korea Research Institute of Bioscience and Biotechnology (KRIBB)
Abstract
Abstract
Background
Synaptotagmin 11 (SYT11) plays a pivotal role in neuronal vesicular trafficking and exocytosis. However, no independent prognostic studies have focused on various cancers. In this study, we aimed to summarize the clinical significance and molecular landscape of SYT11 in various tumor types.
Methods
Using several available public databases, we investigated abnormal SYT11 expression in different tumor types and its potential clinical association with prognosis, methylation profiling, immune infiltration, gene enrichment analysis, and protein–protein interaction analysis, and identified common pathways.
Results
TCGA and Genotype-Tissue Expression (GTEx) showed that SYT11 was widely expressed across tumor and corresponding normal tissues. Survival analysis showed that SYT11 expression correlated with the prognosis of seven cancer types. Additionally, SYT11 mRNA expression was not affected by promoter methylation, but regulated by certain miRNAs and associated with cancer patient prognosis. Moreover, aberrant SYT11 expression was significantly associated with immune infiltration. Pathway enrichment analysis revealed that the biological and molecular processes of SYT11 were related to clathrin-mediated endocytosis, Rho GTPase signaling, and cell motility-related functions.
Conclusions
Our results provide a clear understanding of the role of SYT11 in various cancer types and suggest that SYT11 may be of prognostic and clinical significance.
Publisher
Research Square Platform LLC
Reference34 articles.
1. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48. doi:10.3322/caac.21763.
2. Repurposing approved non-oncology drugs for cancer therapy: a comprehensive review of mechanisms, efficacy, and clinical prospects;Mohi-Ud-Din R;Eur J Med Res,2023
3. Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends;Sun Q;Signal Transduct Target Ther,2023
4. Combining immune checkpoint inhibitors with chemotherapy in advanced solid tumours: A review;Larroquette M;Eur J Cancer,2021
5. Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics;Fagerberg L;Mol Cell Proteomics,2014